Insmed’s (INSM) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Insmed (NASDAQ:INSM) in a report issued on Tuesday morning,Benzinga reports. HC Wainwright currently has a $90.00 target price on the biopharmaceutical company’s stock.

Other equities analysts have also issued research reports about the company. Guggenheim reissued a “buy” rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. raised their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. Bank of America boosted their price target on Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $94.00.

Insmed Price Performance

INSM stock opened at $68.96 on Tuesday. The firm has a market cap of $12.54 billion, a P/E ratio of -12.34 and a beta of 1.07. The firm’s fifty day moving average is $74.61 and its 200 day moving average is $73.55. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Research analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the transaction, the insider now owns 97,083 shares of the company’s stock, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the business’s stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the transaction, the chief executive officer now owns 233,924 shares of the company’s stock, valued at approximately $16,412,107.84. This trade represents a 2.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 471,797 shares of company stock worth $37,621,239 in the last 90 days. 3.00% of the stock is currently owned by insiders.

Institutional Trading of Insmed

Several institutional investors and hedge funds have recently modified their holdings of the company. Elequin Capital LP purchased a new stake in Insmed in the 4th quarter worth $28,000. Steward Partners Investment Advisory LLC grew its position in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares in the last quarter. NBC Securities Inc. bought a new stake in Insmed during the 1st quarter valued at approximately $49,000. V Square Quantitative Management LLC lifted its holdings in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares in the last quarter. Finally, Spire Wealth Management bought a new position in Insmed in the 4th quarter worth approximately $47,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.